Evidence map›Paper›PMID 42064918›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Inherited genetic risk factors in young-onset lung cancer.

Myvizhi Esai Selvan, Bonnie Elyssa Gould Rothberg, Abhijit A Patel, Jian Sang, Amir Horowitz, David C Christiani, Robert J Klein, Zeynep H Gümüş

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Myvizhi Esai SelvanDepartment of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4640-5727
Bonnie Elyssa Gould RothbergYale Cancer Center, New Haven, CT.ORCID 0000-0002-8919-4467
Abhijit A PatelYale Cancer Center, New Haven, CT.ORCID 0000-0003-3943-5610
Jian SangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-4953-3417
Amir HorowitzDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-3100-2810
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-0301-0242
Robert J KleinDepartment of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-3539-5391
Zeynep H GümüşDepartment of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-7364-2202

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Genetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1M
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in BloodU01CA233364 · NCI · YALE UNIVERSITY · PI PATEL, ABHIJIT, SKATES, STEVEN J · 2018 to 2022
$3.4M
Whole Genome Sequencing to Discover Familial Myeloma Risk GenesR01CA167824 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIPKIN, STEVEN M, OFFIT, KENNETH · 2012 to 2016
$1.9M
PRIMAVO: Interactive exploration of cancer patient precision immune monitoring data in clinical trialsR33CA263705 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GUMUS, ZEYNEP HULYA · 2021 to 2021
$1.5M
Prognostic markers in metastatic melanomaK08CA151645 · NCI · YALE UNIVERSITY · PI GOULD ROTHBERG, BONNIE ELYSSA · 2010 to 2014
$527k
NCATS NIH HHS UL1 TR004419NCI NIH HHS K08 CA151645NCI NIH HHS R01 CA167824NCI NIH HHS R01 CA244948NCI NIH HHS R33 CA263705NCI NIH HHS U01 CA209414NCI NIH HHS U01 CA233364
6 · The paper itself

Abstract

Introduction: Lung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. Methods: We performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age <45 years) and 6,359 older patients at gene and gene-set levels using Fisher's exact test, stratified by histology, sex, and smoking status. Polygenic risk scores (PRS) derived from common variants were also evaluated. Results: Young-onset patients carried a higher burden of rare germline P/LP variants in DNA damage response (DDR) genes (including Conclusion: Young-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.

Indexed as

DNA damage resonsegermlinelung canceryoung-onset lung cancer

Identifiers

PMID42064918
PMCPMC13127507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.